ClinicalTrials.gg
RecruitingNCT07348484Updated Nov 5, 2026

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

An observational study in Chronic Kidney Disease, sponsored by Instituto de Investigación Biomédica de Salamanca. Recruiting at 1 site in Spain. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Instituto de Investigación Biomédica de Salamanca · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.

Planned enrollment
20th of 34
300 · median 397
Started
2026
with 14 others
Observational
34 of 188
10 open now
Primary completion
2028-04
later than 35 of 54 live
Registered
169th of 188
by date

Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 20th largest by planned enrollment of the 34 observational ones that give a count, is one of 15 that started in 2026, is one of 34 observational ones, reaches primary completion later than 35 of the 54 other live ones, and was the 169th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Renal Insufficiency, Chronic with a site in Spain, or all of them as a file.
02

Study summary

This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

No investigational product is assigned, and medical practice or prescription patterns are not altered.

Read the detailed description

This is a real-world, observational study with prospective follow-up and retrospective baseline data when available, conducted at the Nephrology Department of the University Hospital of Salamanca, Spain.

The project integrates translational and clinical components:

  1. validation of a urinary biomarker panel obtained through differential proteomics for early detection and monitoring of CKD progression, and
  2. evaluation of the effectiveness and safety of SGLT2i in routine clinical practice.

A total of 300 adults with CKD stages 2-4 will be included (150 initiating SGLT2i and 150 matched controls). Participants will be followed for 12 months (baseline, 6, and 12 months). Data will be extracted exclusively from electronic health records and laboratory systems.

The primary outcome is the annual decline rate of estimated glomerular filtration rate (eGFR, CKD-EPI 2021). Secondary outcomes include a composite renal endpoint (≥40% sustained eGFR decline, renal replacement therapy, transplantation, or renal death), cardiovascular hospitalization, all-cause mortality, adverse drug reactions (ADRs), and real-world patterns of SGLT2i use.

Exploratory analyses will assess associations between urinary biomarkers and clinical outcomes.

The study follows Spanish regulations for observational studies with medicinal products (Real Decreto 957/2020), with ethics approval and informed consent for biological samples.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • SGLT2 inhibitors
  • empagliflozin
  • urinary biomarker
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants with chronic kidney disease (CKD) stages 2-4.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • Diagnosed with chronic kidney disease (KDIGO stages 2-4)
  • ≥12 months
  • Available clinical and laboratory data in the electronic medical record

Exclusion criteria

Exclusion Criteria:

  • Current or recent renal replacement therapy or kidney transplantation
  • End-stage renal disease
  • Participation in interventional trials that may affect outcomes
  • Allergy or intolerance to SGLT2i (for exposed cohort)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Empagliflozin Treatment Group

    Participants with chronic kidney disease (CKD) stages 2-4 will receive oral empagliflozin (10-25 mg daily) for 12 months. Urinary and plasma samples will be collected at baseline, 6 months, and 12 months to evaluate the urinary biomarker panel, renal function (eGFR), and treatment safety.

    Drug: Empagliflozin

  • Control group

    Adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification) managed in nephrology outpatient clinics without initiation of SGLT2 inhibitors at baseline or during follow-up. These patients receive standard clinical care according to local and national guidelines. They are followed on the same schedule (baseline, 6, and 12 months) and have identical variables collected from electronic health records and laboratory systems. Reasons for non-initiation of SGLT2i are documented systematically and may include: Not meeting indication criteria established by the Spanish National Health System (e.g., albumin-to-creatinine ratio \<200 mg/g, eGFR \<20 mL/min/1.73 m² for empagliflozin or \<25 for dapagliflozin), or Clinical contraindications or conditions such as significant hypovolemia or hypotension, recurrent urinary or genital infections, or hypersensitivity. Control patients will be censored in the primary analysis if they later start SGLT2i therapy (cross-over).

Interventions

  • Oral empagliflozin (10-25 mg daily) for 12 months

06

What researchers measure

Primary outcomes

  1. Change in urinary biomarker panel expression (proteomic fingerprint)

    Quantitative assessment of urinary biomarkers (including KIM-1, transferrin, IGFBP7, TIMP-2, among others) to evaluate disease progression and treatment response. Urinary biomarkers will be assessed using liquid chromatography-mass spectrometry (LC-MS/MS)-based differential proteomic analysis. Biomarker expression will be quantified as log2 fold change with false discovery rate (FDR) correction. Selected biomarkers will be validated using enzyme-linked immunosorbent assay (ELISA) or equivalent immunoassays. Biomarker concentrations will be normalized to urinary creatinine levels.

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR)

    Evaluation of renal function improvement or stabilization during SGLT2 inhibitor treatment.

    Time frame: Baseline, 6 months, 12 months

  2. Histopathological improvement of renal tissue (animal study)

    Monthly analysis of renal fibrosis, inflammation, and extracellular matrix accumulation in preclinical models treated with empagliflozin.

    Time frame: Monthly up to 9 months

  3. Monitoring of adverse events of empagliflozin in CKD patients without diabetes

    Adverse events (AEs) will be recorded and classified according to Common Terminology Criteria for Adverse Events (CTCAE, latest version), including severity grading and assessment of causality related to treatment. Serious adverse events (SAEs) and discontinuations due to AEs will be specifically tracked by the investigator.

    Time frame: From baseline to 12 months

  4. Change in estimated glomerular filtration rate (eGFR)

    Change in renal function assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation during empagliflozin treatment using the Serum creatinine-based CKD-EPI equation.

    Time frame: From baseline to 12 months

  5. Change in serum creatinine

    hange in serum creatinine levels to assess renal safety during treatment with empagliflozin by standard clinical laboratory assay (mg/dL).

    Time frame: From baselinte to 12 months

  6. Change in urinary albumin-to-creatinine ratio

    Change in urinary albumin-to-creatinine ratio as a marker of renal damage and safety during empagliflozin treatment by standard urine laboratory testing (mg/g creatinine).

    Time frame: From baseline to 12 months

  7. Change in serum electrolyte levels

    Change in serum sodium and potassium levels to evaluate electrolyte safety during empagliflozin treatment by standard clinical laboratory testing (mmol/L).

    Time frame: From baseline to 12 months

  8. Change in liver function tests

    Change in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to assess hepatic safety by standard clinical laboratory assays (U/L).

    Time frame: From baseline to 12 months

  9. Change in glycated hemoglobin (HbA1c)

    Change in HbA1c levels to monitor metabolic safety in non-diabetic CKD patients treated with empagliflozin by standard laboratory assay (%).

    Time frame: From baseline to 12 months.

  10. Change in hematological parameters

    Change in complete blood count parameters to evaluate hematological safety during treatment by standard clinical laboratory testing.

    Time frame: From baseline to 12 months

  11. Change in blood pressure

    Assessment of changes in both blood pressures (systolic and diastolic), by Standard sphygmomanometer measurement (mmHg).

    Time frame: From baseline to 12 months

  12. Change in body weight

    Change in body weight to assess tolerability and volume status during empagliflozin treatment by calibrated clinical scale (kg).

    Time frame: From baseline to 12 months

  13. Discontinuation due to treatment intolerance

    Number and proportion of participants who permanently discontinue empagliflozin due to treatment-related intolerance or adverse events. It will be achieved trough clinical visit records and adverse event reporting.

    Time frame: From baseline to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

Access criteria: Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 24 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Jan 2026 → Apr 2026, primary completion Dec 2027 → Apr 2028 and completion Mar 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Jan 16, 2026
StartActual
Apr 1, 2026was Jan 2026
Primary completionEst.
Apr 2028was Dec 2027
CompletionEst.
Dec 2028was Mar 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
Hospital Universitario de Salamanca is now Recruiting
Nov 5, 2026
Start date
Jan 2026→Apr 1, 2026 (actual)
Nov 5, 2026
Primary completion
Dec 2027→Apr 2028
Nov 5, 2026
Study completion
Mar 2028→Dec 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    Hospital Universitario de Salamanca is now Recruiting
    Start date Jan 2026→Apr 1, 2026 (now actual)
    Primary completion Dec 2027→Apr 2028
    Study completion Mar 2028→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07348484
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Apr 1, 2026
Primary completion
Apr 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Carlos Martínez Salgado, PhD
Contact
carlosms@usal.es
+34616129633
Carlos Martínez Salgado, PhD
principal investigator · University of Salamanca
Pilar Fraile Gómez, MD, PhD
principal investigator · University of Salamanca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion